MedTrace Logo

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

NCT04124003 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-03-10

No results posted yet for this study

Summary

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

Conditions

  • Healthy Participants

Interventions

DRUG

rosuvastatin

Specified dose on specified days

DRUG

BMS-963272

Specified dose on specified days

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2020-01-03
Completion
2020-01-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124003 on ClinicalTrials.gov